{"entity":{"id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ASP546C in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., now recruiting.","summary":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors is a phase 1/2 interventional study registered as NCT07488676 by Astellas Pharma Global Development, Inc., with 150 participants planned, started 2026-05-04 and due to reach its primary completion in 2029-07-31. Interventions recorded: ASP546C.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07488676","url":"https://clinicaltrials.gov/study/NCT07488676"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07488676","phase":"1/2","setting":"A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types","sponsor":"Astellas Pharma Global Development, Inc.","enrolled":150,"outcomes":[]},"route":"/trials/nct07488676/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}]}}